ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Pooled it
- Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601).Journal of geriatric oncology · 2024Trial
- Evaluating the Test-Retest Reliability and Measurement Error of a Sit-Stand-Power Test in Individuals Treated for Cancer.Integrative cancer therapiesTrial
- Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study.Journal of the National Cancer Institute · 2026Article
- Personalizing cancer care for older adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Frailty transitions and associated factors in older cancer survivors in the USA: using a multi-state modeling.Journal of cancer survivorship : research and practice · 2026Article
- Epigenetic age acceleration measures and chemotoxicity in older adults with early breast cancer.GeroScience · 2026Article
- Prognostic value of pan-immune-inflammation in breast cancer patients with lymph node metastasis and neoadjuvant therapy.Medicine · 2025Observational
- Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.The oncologist · 2025Article
- Gerotherapeutics: aging mechanism-based pharmaceutical and behavioral interventions to reduce cancer racial and ethnic disparities.Journal of the National Cancer Institute · 2025Review
- Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings.The oncologist · 2025Article
- Longitudinal trajectories of a claims-based frailty measure during adjuvant chemotherapy in women with stage I-III breast cancer.The oncologist · 2024Article
- EDITORIAL : Special Edition on Geriatric Oncology.Translational oncology · 2024Article
- Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study.Journal of cancer survivorship : research and practice · 2024Observational
- An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer.Current oncology reports · 2024Review
- Article
- Article
- Geriatric assessment-derived deficit accumulation and patient-reported treatment burden in older adults with bladder cancer.Journal of the American Geriatrics Society · 2024Article
- Epigenetic and inflammatory markers in older adults with cancer: A Young International Society of Geriatric Oncology narrative review.Journal of geriatric oncology · 2024Review
- Toxicity risk score and clinical decline after adjuvant chemotherapy in older breast cancer survivors.Journal of the National Cancer Institute · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
purposeOlder breast cancer survivors are at increased risk of clinical decline after adjuvant chemotherapy. This study aimed to evaluate whether inflammatory markers assessed before adjuvant chemotherapy are associated with chemotherapy-induced clinical decline in a population of fit older adults with breast cancer.
methodsIn a prospective study of women age ≥ 65 years with stage I-III breast cancer treated with chemotherapy, we measured interleukin-6 (IL-6) and C-reactive protein (CRP) prechemotherapy (T1). We assessed frailty status, using a Deficit Accumulation Index (DAI; categorized as robust, prefrail, and frail), at T1 and postchemotherapy (T2). The population of interest was robust women at T1. The primary outcome was chemotherapy-induced decline in frailty status, defined as decline in DAI from robust (T1) to prefrail or frail (T2). Multivariable logistic regression was used to examine the association between inflammatory markers and the primary outcome, adjusted for sociodemographic and clinical characteristics.
resultsOf the 295 robust women at T1, 76 (26%) experienced chemotherapy-induced decline in frailty status, among whom 66% had high IL-6, 63% had high CRP, and 46% had high IL-6 and CRP at T1. After adjusting for sociodemographic and clinical characteristics, women with high IL-6 and CRP had a > three-fold (odds ratio, 3.52; 95% CI, 1.55 to 8.01;
conclusionIn this cohort of older women with early breast cancer who were clinically fit before chemotherapy initiation, high IL-6 and CRP prechemotherapy were associated with chemotherapy-induced decline in frailty status independent of sociodemographic and clinical risk factors. Further research is needed to examine whether inflammatory markers can inform more personalized approaches to treating older breast cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.